Skip to main content
IMDX logo

Insight Molecular Diagnostics Inc. (IMDX) Stock: Price, Forecast & Analyst Target

Insight Molecular Diagnostics Inc. (IMDX) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $1.59 (-10.67%), as of the Nov 18, 2026 trading session; market cap $52.1M.

Educational signal · not a buy or sell recommendation · How to read this

$1.59 −$0.19 (-10.67%) Market Cap $52.1M

Insight Molecular Diagnostics Inc. · IMDX · NASDAQ

Insight Molecular Diagnostics Inc. (IMDX) is a molecular diagnostics company focused on researching, developing, and commercializing cancer detection tests. Their key products include DetermaRx for early-stage lung adenocarcinoma and DetermaIO, a gene expression assay.

Price as of Nov 18, 2026

Key Statistics

19 of 100

MoonshotScore v2 · Insight Molecular Diagnostics (IMDX)

Weak
Business Quality Poor (15)
Financial Safety Fragile (11)
Valuation Bubble (7)
Growth Durability Fading (33)
Momentum Slipping (21)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.

  • EPS beat 0 of the last 4 reports
  • Altman Z -32.35 · Piotroski F 3
  • ROE 192.1% · current ratio 1.46 · earnings yield -61.4% · free-cash-flow yield -53.6%

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IMDX (57 recorded, newest six shown)
RecordedScoreBand
18Weak
19Weak
19Weak
19Weak
19Weak
19Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.59
Change on the day-10.67%
Market capitalisation$52.1M—
Shares traded on the day636.1K

Price & events

Other perspectives

Council score for Insight Molecular Diagnostics (IMDX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Negative
Valuation Negative
Growth Durability Weak
Momentum Weak

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Weak

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Insight Molecular Diagnostics (IMDX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Insight Molecular Diagnostics Inc. (IMDX) is listed on NASDAQ. It employs 55 people. The market values it at $52.1M.

2 · Latest results

What do the latest results show for Insight Molecular Diagnostics (IMDX)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Jun 2025$518,000-$10M—
Q3 FY2025$260,000-$11M-$0.34 (diluted)
Q4 FY2025$1M-$23M-$0.72 (diluted)
Q1 FY2026$32,000-$4M-$0.12 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Insight Molecular Diagnostics (IMDX)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -32.35 · Piotroski F 3. Trailing ratios: ROE 192.1% · current ratio 1.46 · earnings yield -61.4% · free-cash-flow yield -53.6%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -32.35 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Insight Molecular Diagnostics (IMDX)?

Short answer · as of

Current published price targets run low $12.00 · high $12.00 · consensus $12.00 · median $12.00 against a quoted price of $1.59 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Insight Molecular Diagnostics scored?

Short answer · as of

A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Rose Hill Acquisition Corporation (ROSE) Named competitor$11.66 Sep 11, 2026$61.7M— Model unavailable
Genetic Technologies Limited (GENE) Named competitor$0.77 Oct 23, 2026$111M— Model unavailable
Foundation Medicine, Inc. (FMI) Named competitor$137.00 Sep 18, 2026—— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$12.00 – $12.00
Consensus target
$12.00
Median target
$12.00

Consensus record · Captured .

Measured against a quoted price of $1.59 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IMDX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IMDX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Insight Molecular Diagnostics (IMDX)?

Read these with our analysis →

Investor Questions: IMDX Stock

These answers are editorial: 1 of these 9 answers is drawn from the IMDX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for IMDX?

IMDX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Insight Molecular Diagnostics Inc. (IMDX) is a molecular diagnostics company focused on researching, developing, and commercializing cancer detection tests.

Is IMDX a good stock to buy?

Stock Expert AI does not rate IMDX buy, sell or hold. Insight Molecular Diagnostics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IMDX stock price today?

The last price recorded for Insight Molecular Diagnostics Inc. (IMDX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the IMDX price target?

The analyst consensus price target for Insight Molecular Diagnostics Inc. (IMDX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for IMDX?

Insight Molecular Diagnostics Inc. faces several key risks. Competition from larger, more established companies in the molecular diagnostics market is a significant challenge.

What are the key factors to evaluate for IMDX?

Insight Molecular Diagnostics Inc. (IMDX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Focus on molecular diagnostics for cancer detection positions the company in a high-growth area of healthcare. Not financial advice.

How frequently does IMDX data refresh on this page?

IMDX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IMDX's recent stock price performance?

Insight Molecular Diagnostics Inc. (IMDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DetermaRx and DetermaIO diagnostic tests. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IMDX overvalued or undervalued right now?

Insight Molecular Diagnostics Inc. (IMDX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 10 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.